MARKET

ALXO

ALXO

Alx Oncology Holdings Inc
NASDAQ
11.21
-0.21
-1.80%
Opening 11:32 03/28 EDT
OPEN
11.45
PREV CLOSE
11.41
HIGH
11.45
LOW
11.01
VOLUME
95.48K
TURNOVER
0
52 WEEK HIGH
17.42
52 WEEK LOW
3.936
MARKET CAP
561.95M
P/E (TTM)
-2.9954
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at ALXO last week (0318-0322)?
Weekly Report · 3d ago
Weekly Report: what happened at ALXO last week (0311-0315)?
Weekly Report · 03/18 09:12
Is ALX Oncology Holdings (NASDAQ:ALXO) Using Debt In A Risky Way?
ALX Oncology Holdings Inc. (NASDAQ:ALXO) has debt on its balance sheet. The company has US$9.64m in debt, but has more cash than debt. The balance sheet is a good indicator of a company's ability to manage its debt levels. ALX oncology has a loss-making business but has a surplus of cash to spend on growth.
Simply Wall St · 03/12 11:17
ALX Oncology Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 03/11 10:49
ALX Oncology Price Target Raised to $20.00/Share From $17.50 by HC Wainwright & Co.
Dow Jones · 03/11 10:49
HC Wainwright & Co. Maintains Buy on ALX Oncology Holdings, Raises Price Target to $20
Benzinga · 03/11 10:39
Weekly Report: what happened at ALXO last week (0304-0308)?
Weekly Report · 03/11 09:12
Big Pharma patent cliffs seen fueling oncology M&A this year
Big Pharma patent cliffs seen fueling oncology M&A this year. Around $182B in revenue is at risk over the next four years due to patent expirations. Cantor Fitzgerald sees between five and 17 acquisition deals for oncologists in 2014. The global market for cancer drugs is expected to grow from $180B in 2022 to $323B in 2028.
Seeking Alpha · 03/10 17:08
More
About ALXO
ALX Oncology Holdings Inc. is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 immune checkpoint inhibitor and bridge the innate and adaptive immune system. Its product candidate, evorpacept, is a CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. It is engaged in focusing on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. Cancer cells leverage CD47, a cell surface protein, as a don’t eat me signal to evade macrophage phagocytosis or as a don't activate T-cells signal that prevents activation of T-cells by dendritic cells. It focuses on combining evorpacept with anti-cancer antibodies, ADCs, and PD-1/PD-L1 immune checkpoint inhibitors. It also has a preclinical program focused on developing ALTA-002, a SIRPa TRAAC that offers ways to engage the innate and adaptive immune response to cancer.

Webull offers ALX Oncology Holdings Inc stock information, including NASDAQ: ALXO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALXO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALXO stock methods without spending real money on the virtual paper trading platform.